Abstract

This work focused on investigating therapeutic efficacy of sacral plexus block combined with dexmedetomidine in preventing catheter-related bladder discomfort in patients receiving transurethral resection of the prostate. Sixty patients undergoing elective prostatectomy were randomized as group D or group M (n=30 each). Both groups were given dexmedetomidine 0.5 μg/kg 10 min before induction of general anesthesia. The severity score of catheter-related bladder discomfort, Richmond agitation sedation scale, visual analog scale score and adverse events at 30 min (T1), 2 h (T2) and 6 h (T3) postoperatively were recorded. 1 d preoperatively, as well as 1 and 3 d postoperatively, the neuropsychiatric function of patients was tested by mini-mental state examination and the incidence of postoperative cognitive dysfunction was observed. Compared with group D, group M had significantly decreased catheter-related bladder discomfort incidence at T1 and T2 (p<0.05), but with the passage of time, difference in the incidence of catheter-related bladder discomfort of both groups at T3 was of no statistical significance (p>0.05). Compared with group D, the visual analog scale scores of group M at T1, T2 and T3 remarkably decreased (p<0.05). Relative to group D, group M had remarkably reduced agitation scores at T1, T2 and T3 (p<0.05). Differences in the side effects rate and postoperative cognitive dysfunction incidence were not significantly different between both groups (p>0.05). Sacral plexus block combined with dexmedetomidine decreases postoperative catheter-related bladder discomfort rate among transurethral resection of the prostate patients and has good comfort and safety.